{"anticipatedPostingDate":"2009-11","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Defined by an absolute circulating donor-derived natural killer cell count of \\>100 cells/microliter 10-13 days after infusion with \\<5% donor T and B cells in the mononuclear population","groups":[{"description":"All patients receiving full study treatment with chemotherapy and radiation, along with natural killer cells, aldesleukin and umbilical cord blood transplant.","id":"OG000","title":"Evaluable Patients"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"10-13 Days Post Infusion","title":"Number of Participants (Patients) With Successful Natural Killer Cell Expansion","type":"SECONDARY","unitOfMeasure":"Participants"}